Beam Therapeutics Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
6
Neutral
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
BEAM
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ currently unprofitable (-57% margin).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
BUY
Target $51.20 (+66.8%)
15 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
BEAM
PFE
—
Trailing P/E
19.4×
-7.0×
Forward P/E
9.4×
-57.2%
Profit Margin
12.4%
-193.1%
Gross Margin
75.8%
-8.1%
ROE
8.9%
279.5%
Revenue Growth
-1.2%
—
Earnings Growth
—
2.19
Beta
0.39
—
Price / Book
—
$3.2B
Market Cap
$149.8B
$15 – $36
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →